

Haematologica
HAEMATOL/2018/215129
Version 4

Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

Elena Santagostino, Maria Elisa Mancuso, Cristina Novembrino, Luigi Piero Solimeno, Armando Tripodi, and Flora Peyvandi

Disclosures: ES acted as member of speaker bureau and/or advisory board sponsored by Bayer, Pfizer, CSL Behring, Novo Nordisk, Grifols, Baxalta/Shire, Bioverativ, Sobi, Octapharma, Kedrion, Spark and Roche. MEM acted as member of speaker bureau and/or advisory board sponsored by Bayer, Pfizer, CSL Behring, Novo Nordisk, Grifols, Baxalta/Shire, Bioverativ, Sobi, Octapharma, Kedrion and Roche. CN acted as member of advisory board sponsored by Roche and Werfen. LPS acted as member of speaker bureau and/or advisory board sponsored by CSL Behring, Novo Nordisk, Baxalta/Shire and Sobi. AT acted as member of speaker bureau and/or advisory board sponsored by Novo Nordisk, Roche and Werfen. FP acted as member of speaker bureau and/or advisory board sponsored by Ablynx, Novo Nordisk, Grifols, Baxalta/Shire, Sobi, Kedrion and Roche.

Contributions: ES and MEM performed research and wrote the manuscript, CN performed laboratory tests, LPS performed surgery, AT and FP revised the manuscript